CoChat

Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study

Díaz Rubio, E., Tabernero, J., van Cutsem, E., Cervantes, A., André, T., Humblet, Y., Soulié, P., Corretgé, S., Kisker, O., de Gramont, A. · 2005 · Journal of Clinical Oncology
Cited by 155

The DOI matches its Crossref record.

Abstract

3535 Background: Cetuximab (Erbitux), an IgG1 monoclonal antibody that specifically targets EGFR the receptor, is effective in combination with irinotecan or irinotecan/5-FU/FA in patients with EGFR-expressing mCRC in the first and second-/subsequent-line settings. The study was designed to evaluate the safety and efficacy of cetuximab in combination with FOLFOX-4 as first-line treatment. Methods: Pts with non-resectable EGFR-expressing mCRC, with no prior chemotherapy, were treated with cetuximab (400 mg/m2 week 1 and 250 mg/m2 weekly thereafter) plus FOLFOX-4 (every 2 weeks: oxaliplatin 85 mg/m2, day 1; FA 200 mg/m2 IV 2h and 5-FU 400 mg/m2 IV bolus followed by 600 mg/m2 IV for 22h, days 1 and 2) until progressive disease (PD) or unacceptable toxicity. Preliminary Results: Of the 62 pts, median ECOG performance status 0 (0–2), screened, 52 pts (84%) had EGFR-expressing metastatic disease, 43 pts, median age 65 yrs (range 43–78) were finally enrolled. All of the patients are assessable for safety and efficacy. Main adverse events grade 3/4 (pts ≥10%, multiple cycle) observed per pt: acne-like rash 30.2%, diarrhea 25.6%, neurotoxicity 25.6%, neutropenia 20.9%, stomatitis/mucositis 16.3%. The efficacy data on 42 pts yielded an overall confirmed response rate of 72%, comprising 4 (9%) complete responses (CR) and 27 (63%) partial responses (PR). There were also 10 (23%) pts with stable disease to yield a disease control rate of 95%. 8 pts are still on treatment. PFS is 10.2 months. To date, 10 pts have undergone surgery of their metastases: 8 for liver, 1 for lung, 1 for suprarenal gland metastases (9 R0 resections). Conclusions: The combination of cetuximab and FOLFOX-4 has an acceptable safety profile and demonstrates advantages in response rate in the first-line treatment of patients with EGFR-expressing mCRC. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck, Merck KGaA Amgen, Baxter, Roche, sanofi-aventis Merck KGaA Bristol-Myers Squibb, Lilly Oncology, Merck, Roche, sanofi-aventis Lilly Oncology, Roche, sanofi-aventis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.23.16_suppl.3535

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 155

Metadata

Authors
Díaz Rubio, E., Tabernero, J., van Cutsem, E., Cervantes, A., André, T., Humblet, Y., Soulié, P., Corretgé, S., Kisker, O., & de Gramont, A.
Venue
Journal of Clinical Oncology
Published
2005-06
Volume
23
Issue
16_suppl
Pages
3535-3535
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2243460469
Cited by
155
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.3535
The paper
Díaz Rubio, E., Tabernero, J., van Cutsem, E., Cervantes, A., André, T., Humblet, Y., Soulié, P., Corretgé, S., Kisker, O., & de Gramont, A. (2005). Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.3535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.